Relapse & Recovery · Hayward, CA
You knew the treatment was working because one ordinary morning you noticed you had made the coffee without negotiating with yourself first. The fog had lifted enough to forget it had ever been there. And then, weeks or months later, something shifts. Sleep gets ragged. The small tasks start to feel heavy again. A thought you hadn’t heard in a while turns back up, quieter at first, then less quiet. The fear that arrives with it is specific and brutal: it’s coming back, and everything I did was for nothing.
That fear is understandable, and it is wrong. When depression improves and then starts to return, it can feel like the progress evaporated. But a returning symptom is not a verdict on the treatment. It usually means something that helped before needs to be protected, adjusted, or rebuilt. The conclusion is not “nothing works.” The more accurate, more useful conclusion is: something worked, and now the plan needs attention again.
This piece is about what to do in that window, when symptoms are creeping back but you are not yet in crisis. The early steps are the ones with the most leverage, and most of them are things you and your provider can start this week.
Coming back isn’t starting over.
Recurrence is the rule, not the exception
Here is the fact that reframes everything else, and it is worth sitting with for a second. Depression, for many people, is a recurrent illness. In a study that followed people with major depression for ten years, nearly two-thirds had at least one recurrence, and the risk of another episode rose by roughly 16% with each one that came before.[2] A broad review of the recurrence literature reached the same place from a different angle: recurrence reflects an underlying vulnerability, and a history of prior episodes is one of the strongest predictors of the next.[1]
Read in the wrong frame, those numbers sound like a sentence. Read correctly, they are the opposite. If recurrence is common, then a returning symptom is not evidence that you are uniquely broken or that your treatment was a fluke. It is a known feature of the condition, one that clinicians plan for. The plans exist because the pattern is expected. That is why the national treatment guidelines devote a whole section to relapse prevention rather than treating it as a surprise.[13]
It also means the most important variable is not whether symptoms can return. It is how early you catch them when they do.
Catch it in the prodrome, not the crisis
Depression rarely slams the door all at once. It tends to come back the way it often started, gradually, through a set of small changes that are easy to explain away one at a time. The clinical name for that early phase is the prodrome, and learning to read yours is one of the highest-value skills a person with recurrent depression can build.
The signs to watch are the ordinary ones: sleep slipping earlier or later, appetite changing in either direction, motivation thinning out, irritability rising, concentration fraying, pulling back from people, hygiene or chores sliding, losing interest in the things that usually keep you tethered, and the return of hopeless or self-critical thoughts. None of these on its own proves a relapse. Together, trending in the wrong direction over a couple of weeks, they are a signal worth respecting.
There is good reason to take the quiet version seriously. Residual symptoms left over after a partial recovery are among the most powerful predictors of relapse we have. In one classic study, people who finished a depressive episode with lingering residual symptoms relapsed early at a rate of 76%, compared with 25% of those who cleared more completely.[3] Those leftover symptoms often turn out to be the same ones that announce the next episode, which is why some researchers describe residual symptoms and prodromal symptoms as two views of the same thing.[4] Sleep deserves a special mention here: in one cohort, residual insomnia was associated with a roughly fivefold increase in the odds of relapse.[5]
The practical takeaway is plain. You do not need to wait until you are in crisis to act, and you should not. Earlier action gives you more options and easier ones.
Catch it small, or watch it grow.
Two findings that explain why the quiet phase — before a crisis — is the window with the most leverage.
People who finished an episode with residual symptoms relapsed early at 76%, versus 25% who cleared more fully. Those leftover symptoms often become the warning signs of the next episode.
Staying on a medication that worked cut the odds of relapse by about 70% across 31 trials. The single biggest reason not to quietly stop once you feel better.
Both numbers point the same way: the leftover, low-grade signs are the highest-yield place to act. Earlier action gives you more options and gentler ones.
Tell your provider what changed
When you report a returning symptom, a good clinician is not just noting that depression is back. They are trying to figure out what kind of return this is, because the answer changes the plan. The questions tend to cluster around a few things, and you can save time by thinking them through before the appointment.
Did anything change with medication? Stopping, lowering, or taking it less consistently is one of the most common and most fixable reasons symptoms return. Did sleep get worse, and did that come first or follow the mood? Has stress, grief, a trauma reminder, or rising anxiety entered the picture? Are alcohol, cannabis, or other substances involved, since they quietly undercut almost every treatment. Are there new medical issues, pain, hormonal shifts, or other medication changes that could be driving mood from the body’s side? And were you fully in remission before this, or only partially better, never quite all the way back?
These details matter because relapse is not one thing. The fix might be restarting a treatment that worked before, adjusting a dose, returning to therapy, shoring up sleep, rebuilding daily structure, or moving to a higher level of care if depression has become harder to treat. The questions are how your provider tells those situations apart. Walking in with the answers turns a vague “I think it’s coming back” into something a clinician can act on the same day.
Early signs depression may be creeping back
Depression usually returns gradually. These are the changes worth tracking over a week or two.
Rebuild the support beams, quickly and small
When symptoms return, the instinct is to wait until you feel better before doing the things that help. Depression sells that order of operations, and it has it backwards. The supports come first, and the feeling follows. This is not a motivational slogan; it is roughly how behavioral activation works, and behavioral activation is one of the better-evidenced psychological treatments for depression. In a large randomized trial, it performed as well as full cognitive behavioral therapy while being simpler to deliver.[8]
The supports worth rebuilding first are unglamorous on purpose: a regular sleep and wake time, meals that actually happen, some movement, contact with people you trust, a return to therapy if you have stepped away, and a few small responsibilities to anchor the day. Do not rely on willpower to carry all of that at once. Keep the goals almost insultingly small. Take a shower. Step outside for two minutes. Answer one message. Water a plant. Attend the appointment.
The reason small works is mechanical. Depression pulls the mind toward enormous conclusions, “I’m back at zero,” “I’ll never hold this together,” and those conclusions are not reachable by argument. They are reachable by small physical actions that quietly contradict them. A shower does not cure anything. It does prove, in a language depression understands, that you are still capable of moving the next inch. Stack enough of those and the story starts to change.
What “it’s coming back” can mean — and the first move that matches.
A returning symptom can have several different drivers. Naming yours is how a clinician picks the right next step instead of guessing.
When the plan needs to step up
Sometimes early steps and support-rebuilding are enough, and the wobble settles. Sometimes it is the front edge of a fuller episode, and the plan needs more than a tune-up. Knowing what the next tiers look like takes some of the fear out of the moment, because there is almost always a next move.
The first and most common is protecting what already worked. If you are on an antidepressant that helped, continuing it is one of the better-supported decisions in psychiatry. A systematic review pooling 31 trials and more than 4,000 patients found that staying on antidepressant treatment cut the odds of relapse by about 70%, dropping the average relapse rate from 41% on placebo to 18% on continued treatment.[6] This is the single biggest reason not to quietly stop a medication once you feel better. If residual symptoms are lingering, adding a structured psychotherapy after the medication has done its part lowers relapse risk further still.[7]
If depression has become genuinely harder to treat across more than one adequate trial, the conversation widens. The large STAR*D study is sobering and clarifying at once: most people eventually reached remission, but the more treatment steps it took to get there, the higher the relapse rate afterward, which is a real-world argument for both persistence and closer follow-up in people who needed several attempts.[9] For treatment-resistant depression, the higher tiers include options like TMS and SPRAVATO (esketamine), and both have evidence specifically on holding a recovery rather than only producing one. TMS responses show meaningful durability over follow-up when paired with a maintenance plan,[10][11] and in a relapse-prevention trial, continuing esketamine plus an oral antidepressant cut the risk of relapse by about half in patients who had reached stable remission, with a number-needed-to-treat of six.[12] If you have already been down the medication road and want to understand what is left, we wrote a fuller map of that in what to do when neither SPRAVATO nor TMS works.
None of these is a step you take alone or on a first wobble. The point of naming them is different. It is to make clear that “harder to treat” is not the same as “out of options,” and that the staircase keeps going.
First steps when depression starts creeping back
Track the prodrome instead of explaining it away. A few small changes trending the wrong way is data, not weakness.
Medication, sleep, stress, substances, new medical issues — and whether you were fully or only partly in remission before.
Regular sleep and wake time, meals, movement, social contact, one small responsibility. Keep the goals almost insultingly small.
Continue or adjust the treatment that helped before. If symptoms are lingering, adding structured therapy lowers relapse risk further.
For harder-to-treat depression, the staircase keeps going — TMS, SPRAVATO, or higher-level care, with closer follow-up.
For clinicians · the sharper version
Relapse vs. recurrence, and where the yield is
Worth keeping the terms distinct, because they imply different time horizons and different decisions. Relapse is the return of the index episode before full recovery is consolidated, typically conceptualized within the continuation phase. Recurrence is a new episode after recovery, the maintenance-phase problem. The two blur at the bedside, but the framing drives whether you are protecting an incomplete remission or preventing a fresh episode in a recovered patient.
The highest-yield clinical move remains chasing residual symptoms to as close to full remission as tolerable. Residual symptomatology after partial response predicted early relapse at 76% vs. 25% in Paykel’s cohort, and the residual-as-prodrome model reframes those leftover symptoms as the same signal that will herald the next episode.[3][4] Residual insomnia is a specific, modifiable lever worth targeting directly.[5]
When symptoms re-emerge, the differential is the work: adherence and dose, recent taper, sleep architecture, substances, intercurrent medical and hormonal contributors, psychosocial precipitants, and whether the prior remission was full or partial. The maintenance evidence base is unusually clear for psychiatry, continuation pharmacotherapy reduces relapse odds ~70%,[6] sequential psychotherapy adds incremental protection (RR 0.84),[7] and for the treatment-resistant tail, esketamine maintenance and durable rTMS protocols both have relapse-prevention data, not just acute-response data.[12][10] The number of steps to remission in STAR*D tracks with subsequent relapse risk, which argues for tighter follow-up density in the multiply-stepped patient.[9]
The takeaway
If depression comes back after treatment worked, you are not starting from nothing. You have already proven the most important thing there is to prove: your brain can respond. That is not a small fact. It is the difference between an unknown and a known problem, and known problems have plans.
The task now is narrow and doable. Catch the relapse early, while it is still quiet. Figure out what changed. Rebuild the supports before you feel like it. And adjust the plan, with your provider, before depression gets louder. You did it once. The path back is shorter the second time, especially when you start walking it early.
Noticing the early signs again?
The best time to adjust the plan is while it’s still quiet. Book a visit and we’ll figure out what changed, protect what worked, and decide the next step together — before depression gets louder.
References
- Burcusa SL, Iacono WG. Risk for recurrence in depression. Clin Psychol Rev. 2007;27(8):959-985. PMID: 17448579 · doi:10.1016/j.cpr.2007.02.005.
- Solomon DA, Keller MB, Leon AC, et al. Multiple recurrences of major depressive disorder. Am J Psychiatry. 2000;157(2):229-233. PMID: 10671391 · doi:10.1176/appi.ajp.157.2.229.
- Paykel ES, Ramana R, Cooper Z, Hayhurst H, Kerr J, Barocka A. Residual symptoms after partial remission: an important outcome in depression. Psychol Med. 1995;25(6):1171-1180. PMID: 8637947 · doi:10.1017/s0033291700033146.
- Fava GA, Fabbri S, Sonino N. Residual symptoms in depression: an emerging therapeutic target. Prog Neuropsychopharmacol Biol Psychiatry. 2002;26(6):1019-1027. PMID: 12452521 · doi:10.1016/s0278-5846(02)00226-9.
- Hiranyatheb T, Nakawiro D, Wongpakaran T, et al. The impact of residual symptoms on relapse and quality of life among Thai depressive patients. Neuropsychiatr Dis Treat. 2016;12:3175-3181. PMID: 28003753 · doi:10.2147/NDT.S124277.
- Geddes JR, Carney SM, Davies C, et al. Relapse prevention with antidepressant drug treatment in depressive disorders: a systematic review. Lancet. 2003;361(9358):653-661. PMID: 12606176 · doi:10.1016/S0140-6736(03)12599-8.
- Guidi J, Fava GA. Sequential combination of pharmacotherapy and psychotherapy in major depressive disorder: a systematic review and meta-analysis. JAMA Psychiatry. 2021;78(3):261-269. PMID: 33237285 · doi:10.1001/jamapsychiatry.2020.3650.
- Richards DA, Ekers D, McMillan D, et al. Cost and outcome of behavioural activation versus cognitive behavioural therapy for depression (COBRA): a randomised, controlled, non-inferiority trial. Lancet. 2016;388(10047):871-880. PMID: 27461440 · doi:10.1016/S0140-6736(16)31140-0.
- Rush AJ, Trivedi MH, Wisniewski SR, et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry. 2006;163(11):1905-1917. PMID: 17074942 · doi:10.1176/ajp.2006.163.11.1905.
- Blumberger DM, Vila-Rodriguez F, Thorpe KE, et al. Effectiveness of theta burst versus high-frequency repetitive transcranial magnetic stimulation in patients with depression (THREE-D): a randomised non-inferiority trial. Lancet. 2018;391(10131):1683-1692. PMID: 29726344 · doi:10.1016/S0140-6736(18)30295-2.
- Senova S, Cotovio G, Pascual-Leone A, Oliveira-Maia AJ. Durability of antidepressant response to repetitive transcranial magnetic stimulation: systematic review and meta-analysis. Brain Stimul. 2019;12(1):119-128. PMID: 30344109 · doi:10.1016/j.brs.2018.10.001.
- Daly EJ, Trivedi MH, Janik A, et al. Efficacy of esketamine nasal spray plus oral antidepressant treatment for relapse prevention in patients with treatment-resistant depression: a randomized clinical trial. JAMA Psychiatry. 2019;76(9):893-903. PMID: 31166571 · doi:10.1001/jamapsychiatry.2019.1189.
- National Institute for Health and Care Excellence (NICE). Depression in adults: treatment and management. NICE guideline [NG222]. Published 2022. nice.org.uk/guidance/ng222. (Cited for relapse-prevention recommendations and risk factors for relapse.)
Comments are closed